Novo Nordisk v. Sun Pharma: 19-Patent Saxenda Dispute Dismissed After 536 Days
Novo Nordisk A/S filed suit against Sun Pharmaceutical Industries in Delaware, asserting 19 patents covering its Saxenda (liraglutide recombinant) injectable product. The case concluded via stipulated dismissal after 536 days — one of the larger patent portfolios asserted in a single ANDA-related pharmaceutical action in the district.
19-Patent Liraglutide Portfolio Asserted Against Generic Entrant
On July 1, 2022, Novo Nordisk A/S filed an infringement action in the District of Delaware against Sun Pharmaceutical Industries, Inc., asserting 19 U.S. patents covering its Saxenda product — a liraglutide recombinant solution for injection (18 mg/3 ml, 6 mg/ml). The asserted portfolio spans formulation, device, and method patents and represents one of the most expansive single-case patent assertions seen in the district for a GLP-1 receptor agonist product. Judge Colm F. Connolly presided over the matter.
The case closed on December 19, 2023, through a Stipulation and Order of Dismissal. The recorded basis of termination is Case Dismissed. The docket order is styled as a stipulated dismissal, reflecting agreement between the parties to end the litigation; the specific terms underlying that agreement are not disclosed in the available public record.
The 536-day duration is consistent with pharmaceutical patent disputes that resolve before trial, often following ANDA-related negotiations or commercial arrangements between brand and generic parties. What drove the resolution — and whether any conditions attach to it — is not determinable from the public docket alone.
See Complete Case & Patent Analysis →Filing to Case Dismissed in 536 days
536 days from filing to dismissal in Delaware District Court
US8579869B2 and 18 further patents — Saxenda liraglutide injection technology portfolio
Any company developing, manufacturing, or seeking to commercialise a liraglutide-based injectable product — including ANDA filers, biosimilar developers, contract manufacturers, or device partners — should conduct a comprehensive FTO analysis against the full 19-patent portfolio asserted in this case. Because none of these patents were adjudicated on the merits, their validity and enforceability remain untested by this proceeding. Product teams targeting GLP-1 injectables cannot rely on this dismissal as clearance.
Official order — verbatim text
The docket records a Stipulation and Order of Dismissal in Case No. 22-896 (CFC). This reflects a joint filing by both parties requesting the court close the case. The basis of termination is recorded as 'Case Dismissed.' No merits ruling on any of the 19 asserted patents — validity, infringement, or enforceability — was entered as part of this disposition.
Case dismissed: what the stipulated resolution means for both parties
Stipulated dismissal ends the litigation by agreement
A stipulation and order of dismissal is a procedural vehicle by which both parties jointly request the court to close the case. The basis of termination is recorded as 'Case Dismissed.' The public record does not disclose whether the dismissal was entered with or without prejudice, or what terms, if any, the parties agreed to as a condition of dismissal.
Recorded: Case DismissedNovo Nordisk exits litigation without a merits adjudication
The dismissal means none of the 19 asserted liraglutide patents received a court ruling on validity or infringement. Novo Nordisk retains its full portfolio on paper. Whether this outcome affects Sun Pharma's ability to launch a generic Saxenda product is not determinable from the public record alone.
No validity ruling enteredSun Pharma avoids an adverse infringement finding
Sun Pharmaceutical faces no court-imposed finding of infringement or injunction based on this proceeding. The dismissal, entered by stipulation, means the 19-patent case ends without a merits decision against the defendant. The commercial implications for Sun Pharma's liraglutide ANDA pathway are not disclosed in the public record.
No infringement finding19-patent portfolio signals the breadth of Novo Nordisk's GLP-1 IP fortress
Asserting 19 patents in a single action signals the depth of Novo Nordisk's IP protection around liraglutide. For other generic or biosimilar developers targeting GLP-1 receptor agonist products, this case highlights the complexity of freedom-to-operate analysis required before any market entry attempt. The resolution without a merits ruling leaves the portfolio's enforceability untested in this proceeding.
GLP-1 IP landscape: high barrierFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | /Search in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Travis J. Murray | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Anne Shea Gaza | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Kimberly A. Beis | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert M. Vrana | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen P. Benson | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the GLP-1 and liraglutide IP space
Forward-looking patent and innovation intelligence derived from Novo Nordisk's 19-patent liraglutide assertion and the broader GLP-1 receptor agonist competitive landscape.
Novo Nordisk's liraglutide IP estate: depth and filing trajectory
Asserting 19 patents in a single action signals that Novo Nordisk has built a multi-generational filing strategy around liraglutide — spanning formulation, device, and method claims across more than a decade. Tracking Novo Nordisk's continuation and divisional filings in this space can reveal where the portfolio is being extended and where potential gaps exist.
Portfolio depth: highGLP-1 receptor agonist patent filing trends: a crowded and growing space
The GLP-1 agonist class — liraglutide, semaglutide, tirzepatide — is attracting intense patent filing activity from both innovators and follow-on developers. Mapping filing trends in GLP-1 formulation and injection device patents can identify where the landscape is densest and where white space may remain for novel delivery approaches.
GLP-1 filing activity: risingSun Pharma's injectable biologics and GLP-1 patent position
Sun Pharmaceutical has an active generic and specialty injectable pipeline. Analysing Sun Pharma's own patent filings in the GLP-1 and injectable peptide space can reveal whether it is building proprietary IP around formulation or device improvements — and how its defensive posture may evolve as the generic liraglutide market develops.
Generic entrant IP activityAdjacent innovation opportunities near the liraglutide delivery IP landscape
The density of Novo Nordisk's 19-patent portfolio around current liraglutide delivery mechanisms suggests that novel injection device architectures, co-formulation approaches, or alternative delivery routes (e.g., oral, implantable) may represent lower-density IP zones. A white-space search around GLP-1 delivery innovation can surface differentiated R&D pathways.
Adjacent delivery routes: opportunitySimilar pharmaceutical patent cases in Delaware District Court
Explore related GLP-1, liraglutide, and injectable biologic patent infringement actions filed in Delaware District Court against generic and biosimilar entrants.
What this case signals for the GLP-1 and liraglutide IP landscape
A 19-patent assertion over a single injectable GLP-1 product reflects a deliberate IP layering strategy — and has direct implications for generic and biosimilar developers.
GLP-1 IP stacking: 19 patents over one product sets a high generic entry bar
Novo Nordisk's assertion of 19 separate patents over Saxenda in a single action reflects a layered IP strategy spanning formulation, device, and method claims. Generic developers targeting liraglutide must navigate each layer independently — invalidating one patent does not clear the path. FTO analysis must be comprehensive across the full portfolio.
Stipulated dismissal without disclosed terms leaves enforceability questions open
Because the case ended by stipulated dismissal with no public terms, none of the 19 patents were tested on validity or infringement. Novo Nordisk's portfolio remains intact and untested by this proceeding. Other generic developers cannot rely on this dismissal as a prior art or invalidity precedent — each patent must be evaluated independently.
A/S v Sun — key questions answered
Novo Nordisk asserted 19 U.S. patents in this action, including US8579869B2, US11097063B2, USRE046363E, US9775953B2, US11311679B2, US9108002B2, US8114833B2, US8920383B2, US9861757B2, US9616180B2, US9968659B2, US7762994B2, US9457154B2, US10220155B2, US10376652B2, US9132239B2, US9687611B2, US10357616B2, and US8684969B2. All relate to Saxenda (liraglutide recombinant) injectable technology.
The case ended on December 19, 2023, via a Stipulation and Order of Dismissal filed in the District of Delaware. The recorded basis of termination is 'Case Dismissed.' The docket order reflects a joint stipulation by both parties. The specific terms of the dismissal are not disclosed in the available public record.
Saxenda is Novo Nordisk's branded liraglutide recombinant injectable product (18 mg/3 ml, 6 mg/ml) approved for obesity treatment. It is a GLP-1 receptor agonist. The Delaware litigation arose in the context of Sun Pharmaceutical's efforts to enter the market with a competing product, triggering Novo Nordisk's assertion of its 19-patent portfolio protecting the product.
No. The case was dismissed by stipulation before any merits adjudication. None of the 19 asserted patents received a court ruling on validity, infringement, or enforceability as part of this proceeding. The full portfolio remains judicially untested from this action.
The dismissal without a merits ruling means other generic developers cannot rely on this case as a validity or invalidity precedent for any of the 19 asserted patents. Each patent must be independently assessed for freedom-to-operate purposes. The undisclosed terms of the stipulation also mean the competitive implications for market entry timing cannot be determined from the public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.